News - Media

Dr. Sayuri Suzuki and colleagues show that the cannabinoid CBGA can ameliorate acute and chronic kidney disease. The manuscript has been published in Scientific Reports.

Dr. Suzuki’s study demonstrates that CBGA, and to a lesser extent CBD, can protect the kidney from damage that can arise acutely as a side-effect of anti-cancer chemotherapy with cisplatin or chronically in obstructive nephropathy and renal fibrosis. The authors demonstrate that CBGA, but not CBD, has a potent inhibitory effect on the channel-kinase TRPM7. They conclude that cannabinoids possess kidney-protective properties, with CBGA having a higher efficacy that is likely due to its dual anti-fibrotic and anti-inflammatory effects paired with TRPM7 inhibition.